Ohio Teacher Wins $10K Summer Getaway and Other Prizes in Tropical Smoothie Cafe
ATLANTA--(BUSINESS WIRE)--Last week, students and teachers in 20 schools across 13 states were treated to a smoothie party hosted by Tropical Smoothie Cafe ® in the Sunshine for Teachers contest. Over $100,000 in cash and prizes were awarded to these worthy teachers and their schools. As the grand prize winner, Danny Kloosterman from Greeneview High School in Jamestown, Ohio won a summer getaway worth up to $10,000 and free smoothies for a year. All first-place winners received a $1,000 cash award and free smoothies for a year. All 20 schools received a donation of $1,000 per school.
'Congratulations to Mr. Kloosterman for winning the grand prize in the Sunshine for Teachers contest,' said Deborah von Kutzleben, Chief Marketing Officer at Tropical Smoothie Cafe, LLC. 'We hope he enjoys his well-deserved summer getaway. On behalf of the Tropical Smoothie Cafe franchisees, we thank every family member and friend who nominated a teacher for this year's program. Reading their stories and celebrating with the teachers at their schools was a highlight for all of us!'
Over 11,000 nominations were submitted nationwide. From those entries, 20 finalists were announced on April 28, which was the opening day for the public voting phase to select the grand prize winner. The individuals who nominated the grand prize and first place winners will receive free smoothies for a year.
The Sunshine for Teachers contest presented by Tropical Smoothie Cafe, was executed in collaboration with Campus Multimedia, a school communication and marketing company that administers such programs on behalf of national brands. 'Campus Multimedia has been honored to work with Tropical Smoothie Cafe on the Sunshine for Teachers contest,' said Karl Mawhinney, CEO and Founder of Campus Multimedia. 'Our teachers deserve our respect and recognition and it has been especially gratifying to see so many worthy entrants in the contest.'
All prizes are subject to the terms and conditions described in the Official Rules.
About Tropical Smoothie Cafe®
Tropical Smoothie Cafe is a national fast-casual restaurant brand built on a mission to Inspire Better®, a commitment that starts with our better-for-you food and smoothies and extends to inspiring better in the communities we serve. Born on a beach in 1997, today Tropical Smoothie Cafe has more than 1,500 locations in 44 states. For the fourth year in a row, the brand was ranked #1 in the Smoothie/Juice Category by Entrepreneur Franchisee 500. For 12 consecutive years, the brand has received the Franchise Times Fast and Serious award, and in 2024 the brand's FUND Score was 905, one of the top scores for franchise concepts analyzed by FRANdata.
About Campus Multimedia
Campus Multimedia is the nation's leader in brand activation for K-12 schools. By connecting our network of over 84,000 schools with aligned brands, we provide resources, recognition, and revenue to strengthen school communities. Our turnkey programs empower schools while helping brands create authentic local connections that drive engagement and lifelong loyalty. Learn more at campusmultimedia.com.
Connect with CM on Facebook, Instagram, and LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
BlackSky Newest Gen-3 Delivers First Very High-Resolution Imagery at Warfighting Speed, 12 Hours Following Launch
Recently collected Gen-3 unit two images have demonstrated the timely operational value of space-based dynamic monitoring in support of strategic and tactical defense and intelligence missions HERNDON, Va., June 10, 2025--(BUSINESS WIRE)--BlackSky Technology Inc. (NYSE: BKSY) has delivered the first very high-resolution images from the company's second Gen-3 satellite just 12 hours following its successful launch last Monday. "In today's national security environment, BlackSky's customers require space-based intelligence that moves at warfighter speed," said Brian O'Toole, BlackSky CEO. "BlackSky's newest Gen-3 satellite has delivered low-latency, very high-resolution imagery on its first day in orbit demonstrating the maturity of our AI-enabled architecture and demonstrates the agile, mission-ready resilience of our commercial capabilities today." Early morning Gen-3, unit two, imagery collected yesterday at 7:45 a.m. China Standard Time over Golmud Air Base, Qinghai Province, China has demonstrated the timely operational value of high-cadence, space-based dynamic monitoring capabilities in support of strategic and tactical surveillance, reconnaissance and tracking defense and intelligence missions. Gen-3 gives decision makers the ability to discern vital aircraft movements, ground vehicle positioning and critical facility operations that can provide valuable real-time context to multisource intelligence efforts. "BlackSky is committed to giving customers an unparalleled operational advantage at disruptive speed, scale and economics. Our real-time dynamic monitoring capabilities offer a strong complement to national space assets, especially in support of time-dominant strategic and tactical operations," said O'Toole. As part of BlackSky's high-cadence, time-diverse constellation, each new Gen-3 satellite is expected to accelerate the development of new customer applications in automated real-time and predictive battlefield monitoring. Gen-3 customers have subscription-based access to high-cadence, time diverse 35-centimeter very high-resolution imagery with AI-enabled automated detection analytics that identify and classify a wide library of vehicles, aircraft, vessels and other objects of military interest. As BlackSky's constellation evolves with the regular addition of Gen-3 satellites, BlackSky will continue to optimize for increased constellation capacity and flexibility giving customers confidence in reliable access to services. About BlackSky BlackSky is a real-time, space-based intelligence company that delivers on-demand, high frequency imagery, analytics, and high-frequency monitoring of the most critical and strategic locations, economic assets, and events in the world. BlackSky owns and operates one of the industry's most advanced, purpose-built commercial, real-time intelligence systems that combines the power of the BlackSky Spectra® tasking and analytics software platform and our proprietary low earth orbit satellite constellation. With BlackSky, customers can see, understand and anticipate changes for a decisive strategic advantage at the tactical edge, and act not just fast, but first. BlackSky is trusted by some of the most demanding U.S. and international government agencies, commercial businesses, and organizations around the world. BlackSky is headquartered in Herndon, VA, and is publicly traded on the New York Stock Exchange as BKSY. To learn more, visit and follow us on X. Forward-Looking Statements Certain statements in this press release may contain forward-looking statements within the meaning of the federal securities laws with respect to BlackSky. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. In addition, forward-looking statements reflect our expectations, plans, or forecasts of future events and views as of the date of this communication. We anticipate that subsequent events and developments will cause their assessments to change. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Additional risks and uncertainties are identified and discussed in BlackSky's disclosure materials filed from time to time with the SEC which are available at the SEC's website at or on BlackSky's Investor Relations website at View source version on Contacts Investor Contact Aly BonillaVP, Investor Relationsabonilla@ Media Contact Pauly CabellonSr. Director, External Communicationsbksypr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
24 minutes ago
- Business Wire
Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ('Bausch + Lomb' or the 'company'), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the 'Issuers'), have launched an offering of €600 million aggregate principal amount of senior secured floating rate notes ('Notes'). In connection with the Notes offering, the company has also launched a partial refinancing of its credit agreement, whereby the company intends to obtain a $2.2 billion new term B loan facility (the 'New Term B Loan Facility') and a new $800 million revolving credit facility (the 'New Revolving Credit Facility'). The company intends to use the net proceeds from the Notes offering and the New Term B Loan Facility, together with borrowings under the New Revolving Credit Facility, to repay certain outstanding borrowings under its existing revolving credit facility, to refinance in full its outstanding term A loans due 2027 and term B loans due 2027, and to pay related fees and expenses, with any remaining amounts to be used for general corporate purposes. The closing of the Notes offering is not contingent upon the closing the New Term B Loan Facility or the New Revolving Credit Facility. The Notes will be guaranteed by the company and each of the company's subsidiaries (other than the Issuers) that are guarantors under the company's credit agreement and will be secured on a first priority basis by liens on the same assets that secure the obligations under the company's credit agreement and the company's outstanding senior secured notes. The foregoing transactions are subject to market and other conditions. There can be no assurance that the company will be able to successfully complete the transactions on the terms described above, or at all. The Notes will not be registered under the Securities Act of 1933, as amended ('Securities Act'), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes will be offered in the United States only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada will be made on a basis, which is exempt from the prospectus requirements of such securities laws. This news release is being issued pursuant to Rule 135c under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. Forward-looking Statements This news release may contain forward-looking information and statements within the meaning of applicable securities laws (collectively, 'forward-looking statements'), including, but not limited to, our refinancing plans and the details thereof, including the Notes offering, the New Term B Loan Facility and the New Revolving Credit Facility, the proposed use of proceeds therefrom and the details thereof, our ability to complete the transactions described in this press release, and the other expected effects thereof. Forward-looking statements may generally be identified by the use of the words 'anticipates,' 'seeks,' 'expects,' 'plans,' 'should,' 'could,' 'would,' 'may,' 'will,' 'believes,' 'potential,' 'pending' or 'proposed' and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb's filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators (including the company's Annual Report on Form 10-K for the year ended Dec. 31, 2024 and its most recent quarterly filings). In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including the assumption that the risks and uncertainties discussed in such filings will not cause actual results or events to differ materially from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
Yahoo
25 minutes ago
- Yahoo
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics SEATTLE, June 10, 2025--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, today announced Chief Business Officer Neela Patel, Ph.D., will speak at BIO 2025 on a panel on "Beyond Bispecifics and ADCs: Conditionally Active Biologics." The panel will be held on Wednesday, June 18, 2025, in Room 206AB from 10:15 to 11:15 a.m. ET during the BIO International Convention, which takes place June 16-19, at the Boston International Convention and Exhibition Center. It is open to all registered attendees. Conditionally active biologics (CABs) are an emerging class of drugs that are safer and more efficacious than existing treatments with the potential to overcome the challenges of current state-of-the-art therapies, including ADCs and bispecifics. While companies working in this field are currently focused on oncology and immunology, many of their technologies can be applied to any protein therapeutic where regulation is required to harness a biology for patient benefit. The moderator-led discussion will explore the scientific and commercial landscape for CABs, including types of conditionally active therapeutic modalities currently in research and development, the status of clinical data for these molecules, recent technological advances, and the current and future environment for financings and deals. Patel is a scientist and business development executive with more than 25 years of leadership in drug discovery and development, project and portfolio management, and pipeline development through external innovation. Prior to joining Bonum in 2022, she was part of the executive team at Good Therapeutics, where, as Chief Business Development Officer she co-led the company's acquisition by Roche and the subsequent spinout of Bonum. She will be joined by four panelists representing different perspectives on the technology's potential and challenges, including an investor, an expert in drug development from pharma and scientist executives from biotechnology companies with technologies for regulating biologic therapeutics. Alexandra Cantley, Ph.D., Partner, Polaris Partners Stephen Demerast, Ph.D., Chief Scientific Officer, Tentarix Biotherapeutics Randi Isaacs, MD, Chief Medical Officer, Werewolf Therapeutics John C. Lin, MD, Ph.D., SVP, Immuno-Oncology, Head of Bispecifics R&D, Regeneron Pharmaceuticals Moderator: Michael C. Rice, MS, MBA, SVP, Advanced Therapeutics, Lumanity About Bonum Therapeutics Bonum Therapeutics is a privately held biotechnology company that uses a novel antibody-based mechanism to create regulated and targeted, highly active, and less toxic medicines. Bonum's most advanced program is in preclinical development. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus milestones. Bonum's unique approach takes advantage of the ability of an antibody to bind specifically and competitively to two distinct antigens – a dual-binding antibody (DBA). The technology brings the power and specificity of an antibody to therapeutic control and is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at and connect with us on LinkedIn and Bluesky. View source version on Contacts Bonum Contact: Neela Patel, Therapeutics(425) 375-5369patel@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
